Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer

Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer...

Read more on Medical News Today